Plasma clearance and oxidation of dodecanedioic acid in humans. 1996

G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
Cattedra di Medicina Interna, Universita Cattolica del Sacro Cuore, Roma, Italia.

BACKGROUND Dicarboxylic acids are water-soluble, contrary to monocarboxylic acids, and have a metabolic pathway intermediate between those of lipids and carbohydrates. Our goal was to investigate the plasma turnover and oxidation rate of dodecanedioic acid (C12) in eight healthy male volunteers. METHODS A simultaneous infusion of both cold (0.24 mmol/min corresponding to 0.396 kcal/min) and radiolabeled (1.62 microCi/min) C12 free acid was performed. Blood specimens were sampled over a period of 360 minutes, and 24-hour urine samples were collected to measure the levels of C12 by high-performance liquid chromatography and liquid scintillation. Indirect calorimetry was continuously performed, and expired 14CO2 was collected. Binding of C12 in human plasma was determined in separate experiments using equilibrium dialysis. RESULTS A linear one-compartment model was used to describe the kinetics of labeled C12. Its volume of distribution was 139.02 +/- 10.84 mL/kgbw (mean +/- SE), and its plasma elimination constant was 0.01 +/- 0.004 min-1. The 24-hour urinary excretion of C12 was 3.14 +/- 0.96 mmol, corresponding to about 7% of the administered dose. The amount of C12 oxidized, expressed as percent oxidation, was equal to 35.44 +/- 1.64%. The mean basal value of npRQ (0.80 +/- 0.006) significantly (p < .02) decreased during the infusion to 0.78 +/- 0.01, which is a value close to that theoretically calculated (0.77). The oxidation of free fatty acids was significantly increased at the end of the C12 infusion, whereas the glucose oxidation was reduced to about 50%. CONCLUSIONS The experimental data suggest that C12 might represent a fuel substrate immediately available for tissue energy requirements, because a relevant amount of C12 is promptly oxidized. Its prompt oxidation and its conversion to succinic acid support the use of dodecanedioic acid in parenteral nutrition, especially in insulin-resistance conditions in which glucose uptake and oxidation is impaired.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D003998 Dicarboxylic Acids Acyclic acids that contain two carboxyl groups and have the formula HO2C-R-CO2H, where R may be an aromatic or aliphatic group. Acids, Dicarboxylic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum

Related Publications

G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
March 2000, The Journal of pharmacology and experimental therapeutics,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
January 1995, JPEN. Journal of parenteral and enteral nutrition,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
October 2000, International journal of molecular medicine,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
March 1964, Journal of applied physiology,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
November 1982, Biochimica et biophysica acta,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
January 1968, Metabolism: clinical and experimental,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
November 1990, The American journal of physiology,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
April 1974, Comptes rendus hebdomadaires des seances de l'Academie des sciences. Serie D: Sciences naturelles,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
January 1988, Cancer chemotherapy and pharmacology,
G Mingrone, and A De Gaetano, and A V Greco, and G Benedetti, and E Capristo, and M Castagneto, and G Gasbarrini
November 1990, Metabolism: clinical and experimental,
Copied contents to your clipboard!